News & Updates
Filter by Specialty:
Show Multimedia Only

Nerandomilast slows IPF progression in patients already on antifibrotic therapy
11 Jul 2025
byElvira Manzano
The novel oral PDE4B* inhibitor nerandomilast slows the progression of idiopathic pulmonary fibrosis (IPF) in patients receiving antifibrotic treatment, as shown in the phase III FIBRONEER-IPF trial.